NEW YORK – GenomOncology and Precipio announced Wednesday that they have partnered to integrate GenomOncology's clinical genomic reporting software with Precipio's test for myeloid neoplasms.
Under the partnership, GenomOncology's Pathology Workbench will be used as the tertiary analysis and clinical genomic reporting platform for Precipio's next-generation sequencing-based test for myeloid neoplasms. GenomOncology's software will provide support for variant filtering and interpretation, case review, customizable reporting, and matching appropriate therapy and clinical trial options to each patient, the companies said in a statement.
"The robust knowledgebase embedded in the GenomOncology Pathology Workbench will empower Precipio to advance variant interpretation for their NGS testing," GenomOncology Chief Commercial Officer Garreth Hippe said in a statement. "The solution will accelerate the entire process, from sample to the clinical genomic report, giving healthcare providers faster insights into recommended treatment options."
The software's knowledgebase includes annotations, evidence, clinical trial data, and therapy approvals and guidelines for automated interpretation, the companies noted. It can also be used with additional testing modalities like immunohistochemistry, karyotype, or fluorescence in situ hybridization.
Financial and other terms of the deal were not disclosed.